Anal cancer

News

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

News

Incyte's PD-1 drug brings immunotherapy to anal cancer

Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer

News

ESMO: Incyte's PD-1 treads new ground in anal cancer

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programm

Incyte breaks new ground in anal cancer with EU approval

Incyte's PD-1 drug brings immunotherapy to anal cancer

ESMO: Incyte's PD-1 treads new ground in anal cancer

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks